Skip to main content English

CEM24

The Central European Meeting (CEM)

brings together a multinational, multidisciplinary community of urologists, oncologists, radiotherapists, and all other interested specialities. It is under the auspices of the Central European Urologic Society (CEUS), the national societies of Austria, Croatia, Czech Republic, Hungary, Poland, Romania, Slovakia and Slovenia, as well as the Comprehensive Cancer Center and the Department of Urology of the Medical University of Vienna, on 26th and 27th April 2024.

For approximately 24 years, the CEM has been a successful platform for urological science and education for countries in central Europe. From its inception, it served as a stage for sharing knowledge and know-how between central European countries. This year, we have the CEM in a more modern structure to meet the ever-evolving regional urologic health, education, and scientific needs. Henceforth, the CEM's mission will be to serve as a platform for knowledge transfer, experience exchange, continuous learning and capacity building to empower the next generation of urologic leaders in central Europe.


Program

Location: Hörsaalzentrum (8th floor), AKH Wien

ESU Course - new developments in stone treatment
ROOM HS2

  • 5’ European School of Urology: A unique possibility
    for urological education | E. Liatsikos (GR)

  • 20’ EAU Guidelines recommendations on stone treatment | C. Seitz (AT)

  • 20’ Combined intrarenal surgery – Is this the way to go? | E. Liatsikos (GR)

  • 20’ Technological developments in flexible intrarenal surgery | C. Seitz (AT)

  • 20’ Mini PCNL – A tool or a tale? | E. Liatsikos (GR)

  • 35’ Interactive case discussion on Complications of stone surgery | E. Liatsikos (GR) C. Seitz (AT)  

Workshop I - Hands on endoscopic surgery
ROOM 21+OP4

J. Veser (AT), D. Mun (AT), V. Jahrreiss (AT), D. D'Andrea (AT), M. Kępiński (PL)

Workshop I - Hands on endoscopic surgery
ROOM 21+OP4

J. Veser (AT), D. Mun (AT), V. Jahrreiss (AT), D. D'Andrea (AT), M. Kępiński (PL)

Workshop II - Case-based update on metastatic prostate cancer  
ROOM 29

  • 45’ Metastatic hormone-sensitive prostate cancer (mHSPC) | H. Ofner (AT)
  • 45’ Castration-resistant prostate cancer (CRPC) | G. Kramer (AT)
  • 30’ Genetic testing and therapy | J. Krauter (AT)

Workshop III - Semi-live prostate enucleation for BPE    
ROOM 24

  • 20’ Why do we enucleate – History, body of evidence and rational | S. Ahyai (AT)
  • 20’ Enucleation is enucleation is enucleation – energy sources? | L. Lusuardi (AT)
  • 20’ How to shorten the learning curve? | D. Enikeev (AT)
  • 20’ Tipps and tricks of HoLEP | S. Ahyai (AT)
  • 20’ Tipps and tricks of bipolar EP | L. Lusuardi (AT)
  • 20’ Tipps and tricks of ThuFLEP | D. Enikeev (AT)

Workshop IV - Surgical tips & tricks in uro-oncology  
ROOM 25

  • 30’ Retroperitoneal lymphadenectomy | K. Gust (AT)   
  • 30’ Radical prostatectomy, robotic | M. Remzi (AT)
  • 30’ Radical cystectomy, robotic | J. Dobruch (PL)
  • 30’ Partial nephrectomy, robotic | M. Hora (CZ)

with food (moderated poster walk starts 18:00-19:00)
Poster viewing from 13:00-19:00

Location: Van Swieten Saal, Van-Swieten-Gasse 1a, 1090 Wien

Shahrokh Shariat (AT), Marek Babjuk (CZ), Igor Tomašković (HR), Peter Nyirády (HU),
Piotr Chlosta (PL),  Martha Orsolya (RO), Tomaž Smrkolj (SI), Ivan Minčík (SK)

Chairs: P. Chlosta (PL), P. Nyiradi (HU), I. Sinescu (RO)

  • 8:30-8:35  PCa of intermediate risk profile - case & voting | P. Rajwa (PL)
  • 8:37-8:42  Pro: Radical prostatectomy | C. Mirvald (RO)
  • 8:44-8:49  Pro: Radiation therapy | F. Lakosi (HU)
  • 8:51-8:56  Pro: Focal therapy | N. Hübner (AT)
  • 8:58-9:03  Recurrence after focal therapy - case & voting | P. Rajwa (PL)
  • 9:05-9:10   Pro: Salvage radical prostatectomy | K. Krpina (HR)
  • 9:12-9:17   pT3a N0/8 at salvage RP, PSA persistence,
    PSMA PET CT: 2 LN metastases - case & voting | P. Rajwa (PL)
  • 9:19-9:24    Pro: Salvage radiation therapy | P. Dubinský (SK)
  • 9:26-9:31    Pro: Radio-guided salvage lymphadenectomy | R. Pantar (SI)
  • 9:33-9:38   Pro: ADT + Enzalutamide | J. Franke (AT)
  • 9:40-9:45   Salvage lymphadenectomy but PSA recurrence with
    PET PSMA metachronous singular bone metastasis - case & voting
    | P. Rajwa (PL)
  • 9:47-09:52   Pro: ADT + ARTA  | A. Horváth(HU)      
  • 09:54-09:59  Pro: ADT + ARTA + docetaxel | J. Szalontai (HU)
  • 10:01-10:06  Pro: Genetic testing | I. Pezelj (HR)
  • 10:08-10:13  Pro: Metastasis - directed radiation therapy | M. Miszczyk (PL)
  • 10:15-10:20  ADT + ARTA but PSA rise, liver metastasis - case & voting
    | P. Rajwa (PL)
  • 10:22-10:27   Pro: Chemotherapy | M. Ladurner (AT)
  • 10:29-10:34   Pro: Radioligand therapy | E. Takacsova (SK)
  • 10:36-10:41   Pro: Parp - inhibitor in BRCA negative | T. Fazekas (HU)
  • 10:43-11:00   Take home – 5 most important messages & discussion | G. Kramer (AT)               

 

​​​Chairs: S. Ahyai (AT), I. Minčik (SK), T. Smrkolj (SI)

  • 11:30- 11:37  Are there any limits to RIRS: is PCNL obsolete? | A. Szendrői (HU)
  • 11:40-11:47   Enucleation for BPE – What is new? | T. Hradec (CZ)
  • 11:50-11:57   Landscape of surgical alternatives for large BPE | S. Lenart (AT)
  • 12:00-12:07  HoYag vs TFL. Which laser performs better in lithotripsy? | D.Enikeev(AT)
  • 12:10-12:17   Anterior urethral strictures - What can we do? | Z. Saratlija (HR)
  • 12:20-12:27   Sperm quality deterioration: Is it real and what can we do? | A. Szabó (HU)

Chairs: P. Chlosta (PL), H. Fajkovic (AT), M. Orsolya (RO)
Judges: Harun Fajkovic (AT), Milan Hora (CZ), Igor Tomašković (HR),
Peter Nyirády (HU), Piotr Chlosta (PL), Martha Orsolya(RO), Tomaž Smrkolj (SI),
Ivan Minčík (SK)

  • 13:00-13:05     Anna K. Czech: The assessment of bladder cancer resectability with bimanual palpation
  • 13:07-13:12     Samra Jasarevic: Intermediate- and long-term results after ATOMS (Adjustable Transobturator Male System®) implantation
  • 13:14-13:19      Hanna Hagen: Penile inversion vaginoplasty in transgender women: peri- and postoperative complications and sexual function outcome
  • 13:21-13:26      Cosmin Cozma: Retrograde ureteroscopic treatment for renal lithiasis with sizes between 2 and 4 cm
  • 13:28-13:33       Tamás Fazekas: Magnetic resonance imaging in prostate cancer screening: a systematic review and meta-analysis
  • 13:35-13:40      Costin Petcu: Impact of preoperative serum levels of CYFRA 21-1 on overall survival of patients with cystectomy for muscle-invasive bladder cancer
  • 13:42-13:47      Jan Svihra: The comparison of bilateral and unilateral percutaneous nephrolithotomy, meta-analysis 
  • 13:49-13:54     Maša Alfirević: The association of quality of life (QoL) with urinary diversion
  • 13:56-14:01      Iris Ertl: Clofarabine displays a distinctly superior therapeutic window over gemcitabine in preclinical bladder cancer models
  • 14:03-14:08     Marcin Chlosta: Assessment of Briganti and other nomograms in salvage setting

Chairs: M. Babjuk (CZ), J. Dobruch (PL), I. Tomašković (HR),  

  • 14:30-14:35  Intermediate risk NMIBC- case & voting | A. Brisuda (CZ)
  • 14:37-14:42 Pro: Chemoablation | E. Laukhtina (AT)
  • 14:44-14:49  Pro: Urine - based biomarker in the surveillance | T. Smrkolj (SI)
  • 14:51-14:56  Pro: Adjuvant intravesical chemotherapy | R. Tomaškin (SK)
  • 14:58-15:03  Pro: Adjuvant intravesical BCG therapy | D. Georgescu (RO)
  • 15:05-15:10  Pro: En bloc TURBT | D. D’Andrea (AT)
  • 15:12-15:17 Adjuvant MMC but progression to pT1 HG 5%         
    micropapillary- case & voting | A. Brisuda (CZ)
  • 15:19-15:24  Pro: Adjuvant intravesical BCG therapy | J. Janša (SI)
  • 15:26-15:31  Pro: Early radical cystectomy | R. Pantar (SI)
  • 15:33-15:38  BCG unresponsive pT1 HG 5% micropapillary- case & voting
    | A. Brisuda (CZ)
  • 15:40-15:45  Pro: Radical cystectomy | C.Leitsmann (AT)
  • 15:47-15:52   Pro: Bladder-sparing intravesical therapies | O. Moldoveanu (RO)
  • 15:54-15:59   Progression to cT2N0 HG, eGFR 65- case and voting
    | A. Brisuda (CZ)
  • 16:01-16:06   Pro: Bladder preservation with radio chemotherapy
    | A. Andresanu (RO)
  • 16:08-16:13  Pro: Radical cystectomy first | L. Discalicau (RO)
  • 16:15-16:20  Pro: Neoadjuvant chemotherapy first | K. Oberneder (AT)
  • 16:22-16:27   RC without neoadjuvant therapy pT3 N1, eGFR 60- case & voting | A. Brisuda (CZ)
  • 16:29-16:34  Pro: Adjuvant cisplatin-based chemotherapy | K. Gronostaj (PL)
  • 16:36-16:41   Pro: Adjuvant nivolumab | M. Hassler-Di Fratta (AT)
  • 16:43-16:48  No therapy given; progression with lung metastasis;
    EGFR 60- case & voting | A. Brisuda (CZ)
  • 16:50-16:55  Pro: Enfortumab vedotin + pembrolizumab | K. Gust (AT)       
  • 16:57-17:10  Take home – 5 most important messages & discussion | A. Czech (PL)           

 

Chairs: M. Babjuk (CZ), L. Lusuardi (AT), I. Sinescu (RO)
Judges: S. Shariat (AT), M. Hora (CZ), I. Tomašković (HR), P. Nyirády (HU), P. Chlosta (PL),
M. Orsolya (RO), T. Smrkolj (SI), I. Minčík (SK)

  • 17:30 - 17:37   Austria: V. Jahrreis:
    Outcomes of ureteroscopy and laser lithotripsy (URSL) in pediatric patients for large and very large stones  
  • 17:40 - 17:47   Croatia: M. Alfirevic:
    Neoadjuvant or induction chemotherapy (N/IC) for bladder cancer: “Real world” experience
  • 17:50 - 17:57   Czech Rep.: O. Příman:
    Visualization of prostate cancer prior to biopsy in era of modern imaging methods and modification of following local treatment
  • 18:00 - 18:07   Hungary: I. Kocsmár:
    Molecular prediction of muscle invasion: Can we revise the grading and risk stratification of non-muscle invasive urothelial carcinomas?
  • 18:10 - 18:17   Poland: P. Adamczyk:
    The new dilemma in personalized approach to radical cystectomy in muscle invasive bladder cancer patients
  • 18:20 - 18:27   Romania: L. Maxim:
    High resolution micro - ultrasound or MRI in the diagnosis of prostate cancer  
  • 18:30 - 18:37   Slovakia: O.  Gajdoš:

    Does the transrectal approach still have a place in the perineal biopsy era?
    - Our experience and outcomes.

  • 18:40 - 18:47   Slovenia: K. Cerović:
    Tumor rupture during robot-assisted partial nephrectomy                

Site Map


Registration

This event will be approved by the
Austrian Medical Chamber with 19 DFP points and the European Union of Medical Specialists with 10,5 ECMEC points.

Contact

Gabriele Slaby

Universitätsklinik für Urologie
Währinger Gürtel 18-20
1090 Wien

E-Mail: gabriele.slaby@meduniwien.ac.at
T: +43 (0)1 40400-54785


Hotel

Max Brown 7th District
Schottenfeldgasse 74
1070 Wien


Following rooms capacities are optioned for the
CEM24 participants from 26th April till 28th April 2024:

  • 35 Rooms / Room Type MEDIUM
    > only few rooms available, please consider booking other categories
    169.00 €
    per room/per night incl. breakfast for single use
    189.00 €
    per room/per night incl. breakfast for double use
  • 35 Rooms / Room Type LARGE /
    179.00 € per room/per night incl. breakfast for single use
    199.00 €
    per room/per night incl. breakfast for double use
  • 10 Rooms / Room Type EXTRA LARGE /
    199.00 € per room/per night incl. breakfast for single use
    219.00 €
    per room/per night incl. breakfast for double use
    (including local tax)

All guests are required to register before 29th March 2024


Partners

Platinum

Gold

Silver

Bronze

Copper